What is GIMOTI?
GIMOTI is the only FDA-approved, non-oral, self-administered metoclopramide nasal spray for treating symptoms of acute and recurrent diabetic gastroparesis in adults.
Yanuki
ARTICLE DETAIL
Evoke Pharma Secures Patent for GIMOTI, Extending Market Exclusivity | Arnault Family Increases Control Over LVMH | Novo Nordisk and Hims & Hers Settle Patent Dispute, Collaborate on Weight Loss Medications | Oil Price Volatility Amidst Iran War | Writers Guild Prioritizes Health Plan, AI, and Compensation in Negotiations | Live Nation and Justice Department Reach Settlement in Antitrust Case | Walmart vs BJ’s Wholesale: Which Retailer Is the Better Buy? | Byron Allen Acquires Stake in Starz: What It Means for the Media Landscape | Exxon Mobil Stock Soars on Swiss Exchange Amid Record Volume | Evoke Pharma Secures Patent for GIMOTI, Extending Market Exclusivity | Arnault Family Increases Control Over LVMH | Novo Nordisk and Hims & Hers Settle Patent Dispute, Collaborate on Weight Loss Medications | Oil Price Volatility Amidst Iran War | Writers Guild Prioritizes Health Plan, AI, and Compensation in Negotiations | Live Nation and Justice Department Reach Settlement in Antitrust Case | Walmart vs BJ’s Wholesale: Which Retailer Is the Better Buy? | Byron Allen Acquires Stake in Starz: What It Means for the Media Landscape | Exxon Mobil Stock Soars on Swiss Exchange Amid Record Volume
Business / Pharma
Evoke Pharma Secures Patent for GIMOTI, Extending Market Exclusivity
Evoke Pharma (NASDAQ: EVOK) has secured a patent for its GIMOTI® nasal spray, a treatment for gastroparesis. The U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance, extending market exclusivity to December 2036. This move...
Key Insights
- **Patent Extension:** GIMOTI's market exclusivity extends to December 2036, enhancing Evoke Pharma's revenue stream.
- **Non-Oral Treatment:** GIMOTI® is the only FDA-approved, non-oral, self-administered metoclopramide formulation for diabetic gastroparesis, addressing absorption issues of oral medications. Why does this matter? This unique delivery system provides a significant advantage for patients who struggle with oral medication absorption due to gastroparesis.
- **Strategic Value:** The patent listing in the FDA's Orange Book creates a stronger barrier to generic competition.
In-Depth Analysis
Evoke Pharma's recent patent allowance from the USPTO significantly bolsters its market position for GIMOTI® (metoclopramide nasal spray). This patent, a continuation of U.S. Patent No. 11,517,545, extends market exclusivity until December 2036. GIMOTI is the only FDA-approved, non-oral treatment for acute and recurrent diabetic gastroparesis in adults, offering a crucial alternative for patients with impaired oral medication absorption. The company has also filed an additional U.S. continuation application for further claims related to this patient population, showcasing a layered patent strategy to maximize protection.
The strategic importance of this patent lies in its alignment with GIMOTI's unique positioning. Gastroparesis often compromises the effectiveness of oral medications due to slowed gastric emptying. GIMOTI's nasal spray delivery bypasses this issue, ensuring more predictable drug absorption. Securing this patent and listing it in the FDA's Orange Book creates a substantial barrier to generic competition, safeguarding Evoke's revenue stream for an extended period.
FAQ
When will Evoke Pharma's new GIMOTI patent expire?
The new patent for GIMOTI is expected to expire in December 2036.
What condition does GIMOTI treat?
GIMOTI treats acute and recurrent diabetic gastroparesis symptoms in adults.
Takeaways
- Evoke Pharma has strengthened its market position with a patent extension for GIMOTI, lasting until 2036.
- GIMOTI offers a unique non-oral treatment option for diabetic gastroparesis, addressing issues with oral medication absorption.
- The extended patent life provides Evoke Pharma with a competitive advantage and protects its revenue stream.
Discussion
Do you think this patent extension will solidify Evoke Pharma's market leadership in gastroparesis treatment? Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.